9 November 2026
The Association of European Cancer Leagues (ECL), a non-profit organisation bringing together 35 national and regional cancer leagues, appreciates the efforts of Members of the European Parliament to improve the proposed European Biotech Act. If well-crafted, this initiative has the potential to significantly improve cancer patients’ access to safe, effective, high-quality and affordable biotechnology products, including advanced therapies and biosimilars.
We provide our recommendations for finalisation of the European Parliament SANT and ITRE Committees’ report on the European Biotech Act below.
